All News

Pneumococcal vaccination in pregnancy remains underused in high-risk patients. Maria Marcos, MD, reviews new data, barriers to uptake, and practical vaccination steps for primary care.

Bariatric surgery was associated with lower 2-year costs than GLP-1 therapy in adults with obesity and type 2 diabetes, according to new real-world data.

Jill Liss, MD, outlines how updated evidence, risk stratification, and newer nonhormonal agents can help PCPs confidently manage VMS in everyday practice.

ACOG 2026: James A. Simon, MD, discusses off-label evidence for elinzanetant in breast cancer survivors on anti-estrogenic therapy.

DDW 2026 data show real-world, 52-week IBD outcomes with risankizumab and upadacitinib, including persistence, fewer switches, and hospital visits.

ACOG 2026: James A. Simon, MD, discusses what the results mean for frontline clinician confidence in prescribing the non-hormonal VMS treatment.

DDW 2026: Four-year LUCENT-3 data show mirikizumab maintains composite disease clearance in over 60% of UC patients, marking a first for IL-23p19 inhibitors.

FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.

Network meta-analysis suggests lumateperone add-on therapy improves MDD symptoms most, with minimal weight gain and placebo-like akathisia risk.

ACOG 2026: Jill Liss, MD, details how primary care physicians can safely initiate hormone therapy, manage menopause counseling in brief visits, and more.

ACOG 2026: The new guidance formally introduces clinician-ordered self-collected HPV testing as an option for cervical cancer screening.

ACOG 2026: Genevieve Neal-Perry, MD, discussed her clinical experience with elinzanetant for the treatment of VMS associated with menopause.

A nationally representative study found 71.5% of US women aged 21-49 years were open to HPV self-collection, including 9.7 million who were underscreened or never screened.

Hear from the presenting investigator of late-breaking research presented at ACOG 2026 that found over 80% of pregnancy-related infection deaths were preventable.

Hot flashes and night sweats are just 2 of the myriad symptoms associated with menopause. Click through a quick refresher on the transition and effective treatments.

ACOG 2026: In a nationally representative survey, 75% of women with menopausal symptoms reported sleep problems vs 49.8% without symptoms.

New research shows 35.3% of insured individuals with hypertensive disorders of pregnancy had a preventive care visit within 12 months postpartum.

The FDA approved dextromethorphan hydrobromide-bupropion hydrochloride for agitation associated with dementia due to Alzheimer disease.